Orchard Therapeutics

Orchard Therapeutics is a biotechnology company specialized in gene therapies aimed at treating rare genetic diseases. Since registering in the EU Transparency Register, Orchard Therapeutics has actively engaged in lobbying activities to influence European policy frameworks concerning advanced therapies, regulatory pathways for gene therapies, orphan drug legislation, patient access, and reimbursement policies. The firm prioritizes collaboration with EU institutions, health regulators, and patient groups to advocate for supportive frameworks that accelerate therapeutic development and market access. Their lobbying efforts target relevant EU entities including the European Commission’s DG SANTE, EMA, and the European Parliament’s health-related committees. They focus on ensuring regulatory clarity, incentivizing innovation, and securing sustainable healthcare funding for breakthrough therapies. Orchard Therapeutics combines scientific expertise with policy advocacy to promote patient-centric innovation in the EU biopharmaceutical

Registered name: Orchard Therapeutics (Europe) Limited
EU Transparency Register ID: [Entry ID needed]
Field of activity: Biotechnology, Gene Therapy, Rare Diseases
Registered office: United Kingdom (245 Hammersmith Road, London)
Date of registration: [Date needed from register]

No related lobbyists found.

Biotechnology and pharmaceuticals
Health and medical research
Gene therapy regulatory advocacy
Orphan drug policies
Rare disease patient access and reimbursement

Orchard Therapeutics collaborates and networks with:

Patient advocacy groups specializing in rare diseases and gene therapy
EU-level pharmaceutical and biotech industry associations
Research consortia focused on advanced therapy medicinal products (ATMPs)
Other stakeholders in health innovation and regulatory policy forums

Financial Data:
Total lobbying expenditure by Orchard Therapeutics since registration (approximate annual breakdown):

Year 1: €X – X
Year 2: €X – X
Year 3: €X – X
(Exact financial data required from their EU Transparency Register financial declarations.)

They engage with these EU bodies:

European Commission (DG SANTE, DG RTD)
European Medicines Agency (EMA)
European Parliament Committees (ENVI, ITRE)
Council of the European Union (working groups on pharmaceuticals)

Documented meetings with EU institutions (from registration until June 2025):

Date, EU institution, meeting purpose
Date, EU institution, meeting summary